{"abstract":"The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive commercialization patent license to Ovensa, Inc. headquartered in Ontario, Canada, to practice the inventions embodied in the patent application(s) listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/11/06/2018-24225.html","cfr_references":[],"citation":"83 FR 55556","comment_url":null,"comments_close_on":"2018-11-21","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development November 21, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-24225","effective_on":null,"end_page":55557,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/11/06/2018-24225.xml","html_url":"https://www.federalregister.gov/documents/2018/11/06/2018-24225/prospective-grant-of-exclusive-patent-license-therapeutics-for-insulin-resistance-and-non-alcoholic","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-24225?publication_date=2018-11-06","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-11-06/2018-24225/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":150,"last_updated":"2026-07-28 04:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-11-06/pdf/2018-24225.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-24225.pdf?1541425521","publication_date":"2018-11-06","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/11/06/2018-24225.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T02:13:08Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":55556,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Therapeutics for Insulin Resistance and Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NASH/NAFLD)","toc_doc":"Therapeutics for insulin resistance and Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis","toc_subject":"Prospective Grant of Exclusive Patent License:","topics":[],"type":"Notice","volume":83}